Immunicon Corp. has extended its R&D Agreement with Pfizer for the development of new reagents designed to detect certain undisclosed antigens on circulating tumor cells (CTCs). The collaboration began in February 2003 and is now amended to permit the parties to initiate new clinical research studies by adding new Appendices signed by both parties to the Agreement. A new Phase I trial has been added to the Agreement and will begin enrollment immediately. Byron Hewett, president and chief...